BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of ...
The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - ...
The latest update is out from Addex Therapeutics ( (CH:ADXN) ).
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ...
Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.
Abstract: An accurate understanding of modulation-induced motor losses in inverter-fed traction drives is essential for optimizing inverter operation and designing high-efficiency motor drives.
Investing.com -- Neumora Therapeutics Inc (NASDAQ:NMRA) stock jumped 8.4% in premarket trading Monday after the company reported positive preclinical data for its obesity drug candidate and received ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical stud ...
TipRanks on MSN
Neumora Therapeutics Begins Phase 1 Study for NMRA-898
The latest announcement is out from Neumora Therapeutics, Inc. ( ($NMRA) ). On October 27, 2025, Neumora Therapeutics announced the initiation of ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback